esorubicin profile

esorubicin: RN given refers to parent cpd; synthesized deriv of doxorubicin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	12959501
MeSH ID	M0097338

Synonym
esorubicin

Excerpt	Reference	Relevance
" Pharmacokinetic analysis revealed large interpatient variation in plasma drug levels."	( Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Allen, SL; Budman, DR; Chan, K; Kreis, W; Rottach, C; Schulman, P; Vinciguerra, V; Weiselberg, L, 1988)	0.27
" Each molecule is characterized by original metabolic and pharmacokinetic features, which can be compared to those of the reference anthracyclines, doxorubicin and daunorubicin."	( [Pharmacokinetics of new anthracyclines]. Robert, J, 1988)	0.27
" Esorubicin disappeared from plasma according to a tri-exponential pattern with a terminal half-life of 20."	( Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). Bachur, NR; Crespeigne, N; Davis, TA; Dodion, P; Kenis, Y; Rozencweig, M, 1985)	0.27
"The pharmacokinetic of 4'-deoxydoxorubicin, a new analog of doxorubicin, was compared with that of its parent compound in mice treated with equal and equiactive doses."	( Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Casazza, AM; di Marco, A; Formelli, F; Mariani, A; Pollini, C, 1981)	0.26

Excerpt	Relevance	Reference
" The starting esorubicin dosing schedule was 30 mg/m2 every 3 weeks for good risk patients and 25 mg/m2 every 3 weeks for poor risk patients."	( A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study. Abbott, TM; Alberts, DS; Mason-Liddil, N; O'Toole, RV; Salmon, SE; Stock-Novack, D, 1992)	0.28
" DXDX has minimal activity against non-small cell lung cancer as a single agent at the dosage used in this study."	( Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Blough, RR; Johnson, CM; Kilton, LJ; Lad, TE; Rose, C; Rosen, ST; Rossof, AH; Schor, J, 1990)	0.28
"Forty-six eligible women with advanced metastatic breast cancer were entered on a Phase II trial utilizing esorubicin (4'-deoxydoxorubicin) given in a dosage of 30 mg/m2 intravenously every 3 weeks."	( Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB. Campbell, T; Henderson, IC; Korzun, AH; Muss, HB; Rice, MA; Van Echo, D; Vogelzang, NJ; Wood, W, 1990)	0.28
"4'-Deoxydoxorubicin was given to 15 patients with drug-resistant pediatric malignant solid tumors with the objectives of determining the maximum tolerated dosage and dose-limiting toxicity."	( Phase I study of 4'-deoxydoxorubicin (esorubicin) in children with malignant solid tumors. Avery, L; Douglass, EC; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI, 1989)	0.28
" Dosage levels extended from 35 to 85 mg/m2."	( Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Allen, SL; Budman, DR; Chan, K; Kreis, W; Rottach, C; Schulman, P; Vinciguerra, V; Weiselberg, L, 1988)	0.27
" Phase II trials with esorubicin in this dosage schedule are clearly warranted in a wide variety of metastatic neoplasms including a substantial population of patients who have not received prior chemotherapy."	( Phase I trial of esorubicin (4'deoxydoxorubicin). Alberts, DS; Brooks, R; Garewal, HS; Jones, SE; Robertone, A; Salmon, SE, 1984)	0.27

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	79 (79.00)	18.7374
1990's	21 (21.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	20 (17.39%)	5.53%
Reviews	8 (6.96%)	6.00%
Case Studies	3 (2.61%)	4.05%
Observational	0 (0.00%)	0.25%
Other	84 (73.04%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II, Open Label, Non-Randomized, Efficacy and Safety Study of an Intravenous Formulation of the Anthracycline Analog, GPX-100, in the Treatment of Metastatic Breast Cancer [NCT00123877]	Phase 2	40 participants	Interventional	2005-03-31	Terminated
Phase I Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL) [NCT00030381]	Phase 1	22 participants (Actual)	Interventional	2001-12-31	Terminated(stopped due to Administratively complete.)
Phase II Trial of 4'-IODO-4'-Deoxydoxorubicin in Primary Amyloidosis (AL) [NCT00003853]	Phase 2	45 participants (Anticipated)	Interventional	1999-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	3.76	2	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	3.47	2	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	3.76	2	1	aromatic ether; nitrile; polyether; tertiary amino compound
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	1.96	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	3.06	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.04	3	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	1.97	1	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	4.67	5	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	6.97	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.36	1	1	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.	3.06	1	0	non-proteinogenic L-alpha-amino acid; ornithine	algal metabolite; hepatoprotective agent; mouse metabolite
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.36	1	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	13.51	17	2	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
ribavirin Rebetron: Rebetron is tradename	3.06	1	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	9.23	21	3	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
diaziquone diaziquone: RN given refers to parent cpd. diaziquone : A 1,4-benzoquinone that is substituted at positions 2 and 5 have been replaced by aziridin-1-yl groups and at positions 3 and 6 by (ethoxycarbonyl)amino groups.	3.06	1	0	1,4-benzoquinones; aziridines; carbamate ester; enamine	alkylating agent; antineoplastic agent
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	9.03	17	3	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
7-deoxyadriamycin aglycone 7-deoxyadriamycin aglycone: adriamycin metabolite; RN given refers to (R)-isomer	1.97	1	0
4'-o-methyldoxorubicin 4'-O-methyldoxorubicin: RN given refers to parent cpd(L-lyxo)-(8S-cis)-isomer	2.36	2	0
marcellomycin marcellomycin: pyrromycinone glycoside antibiotic isolated from bohemic acid complex; RN given refers to parent cpd(1R-(1alpha,2beta,4beta))-isomer; structure in fourth source	3.06	1	0
4'-deoxy-4'-iododoxorubicin 4'-deoxy-4'-iododoxorubicin: lipophilic derivative of doxorubicin which differs from the parent compound in substitution of hydroxyl group on the daunosamine sugar moiety	1.97	1	0	organoiodine compound; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
methotrexate [no description available]	3.36	1	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
4'-deoxydoxorubicinol 4'-deoxydoxorubicinol: structure given in first source	2.37	2	0
nogalamycin Nogalamycin: An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA.. nogalamycin : An anthracycline antibiotic isolated from Streptomyces nogalater. It is a DNA intercalator and exhibits anticancer properties.	6.55	3	2
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	1.96	1	0
acivicin [no description available]	3.36	1	1	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
menogaril Menogaril: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.	6.55	3	2
carboplatin [no description available]	4.86	2	1
aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.	5.37	2	1	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	3.06	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
quinine [no description available]	1.98	1	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
methylazoxymethanol acetate Methylazoxymethanol Acetate: The aglycone of CYCASIN. It acts as a potent carcinogen and neurotoxin and inhibits hepatic DNA, RNA, and protein synthesis.	1.96	1	0	azoxy compound
dimyristoylphosphatidylcholine 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).. dimyristoyl phosphatidylcholine : A phosphatidylcholine where the phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).	1.96	1	0	1,2-diacyl-sn-glycero-3-phosphocholine; phosphatidylcholine 28:0; tetradecanoate ester	antigen; mouse metabolite
epicinchonine epicinchonine: structure in first source. cinchonine : Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (S configuration). It occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.	1.98	1	0	cinchona alkaloid
pirarubicin [no description available]	5.99	3	1	anthracycline
adriamycin aglycone adriamycin aglycone: RN given refers to (8S-cis)-isomer	2.37	2	0
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	1.97	1	0
carboxyphthalato-1,2-diaminocyclohexaneplatinum carboxyphthalato-1,2-diaminocyclohexaneplatinum: RN given refers to hydrogen(SP-4-3(1R-trans))-isomer; structure	3.06	1	0
carubicin Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group.	5.99	3	1	anthracycline cation

Condition	Relationship Strength	Studies	Trials
Cancer of Colon [description not available]	5.78	12	2
Colonic Neoplasms Tumors or cancer of the COLON.	5.78	12	2
Cholera Infantum [description not available]	1.96	1	0
Cardiac Diseases [description not available]	3.22	6	0
Benign Neoplasms [description not available]	7.49	12	2
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	3.22	6	0
Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.	1.96	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	7.49	12	2
Leukocytopenia [description not available]	4.45	5	1
Thrombopenia [description not available]	2.65	3	0
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	4.45	5	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.65	3	0
Experimental Leukemia [description not available]	1.96	1	0
Malignant Melanoma [description not available]	10.01	5	2
Experimental Neoplasms [description not available]	2.87	4	0
EHS Tumor [description not available]	2.37	2	0
Experimental Mammary Neoplasms [description not available]	2.37	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	5.01	5	2
Cardiomyopathies, Primary [description not available]	6.53	4	2
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	6.53	4	2
Adenocarcinoma, Basal Cell [description not available]	5.52	6	3
Cancer of Rectum [description not available]	4.27	4	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	5.52	6	3
Rectal Neoplasms Tumors or cancer of the RECTUM.	4.27	4	1
Carcinoma, Anaplastic [description not available]	4.05	3	1
Cancer of Ovary [description not available]	5.02	5	2
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	9.05	3	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	5.02	5	2
Carcinoma, Oat Cell [description not available]	3.76	2	1
Cancer of Lung [description not available]	6.7	12	2
Lung Neoplasms Tumors or cancer of the LUNG.	6.7	12	2
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	3.76	2	1
Metastase [description not available]	5.79	6	4
Cancer of the Uterus [description not available]	3.36	1	1
Local Neoplasm Recurrence [description not available]	4.33	2	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	5.79	6	4
Uterine Neoplasms Tumors or cancer of the UTERUS.	3.36	1	1
Cancer of Stomach [description not available]	3.36	1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	3.36	1	1
Granuloma, Hodgkin [description not available]	3.36	1	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.36	1	1
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	3.36	1	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.36	1	1
Breast Cancer [description not available]	11.44	9	2
Breast Neoplasms Tumors or cancer of the human BREAST.	6.44	9	2
Carcinoma, Bronchial [description not available]	3.36	1	1
Carcinoma, Non-Small Cell Lung [description not available]	4.27	4	1
Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.	3.36	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	4.27	4	1
Arrhythmia [description not available]	1.97	1	0
Cardiac Failure [description not available]	2.38	2	0
Pancoast Syndrome A condition caused by an apical lung tumor (Pancoast tumor) with involvement of the nearby vertebral column and the BRACHIAL PLEXUS. Symptoms include pain in the shoulder and the arm, and atrophy of the hand.	1.97	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	1.97	1	0
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.38	2	0
Hepatocellular Carcinoma [description not available]	3.36	1	1
Cancer of Liver [description not available]	4.05	3	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	3.36	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	4.05	3	1
Cancer of Pancreas [description not available]	4.05	3	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	4.05	3	1
Adenocarcinoma Of Kidney [description not available]	2.38	2	0
Cancer of Kidney [description not available]	3.07	5	0
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	2.38	2	0
Kidney Neoplasms Tumors or cancers of the KIDNEY.	3.07	5	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	2.66	3	0
Blood Diseases [description not available]	4.27	4	1
Epithelial Neoplasms [description not available]	1.97	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	4.27	4	1
Blast Phase [description not available]	1.97	1	0
Acute Myelogenous Leukemia [description not available]	2.66	3	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	1.97	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.66	3	0
Fibromatosis [description not available]	1.97	1	0
Sarcoma, Epithelioid [description not available]	3.29	2	0
Osteogenic Sarcoma [description not available]	1.97	1	0
Fibroma A benign tumor of fibrous or fully developed connective tissue.	1.97	1	0
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	8.29	2	0
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	1.97	1	0
Carcinoma, Epidermoid [description not available]	2.66	3	0
Cancer of Cervix [description not available]	1.97	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.66	3	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	1.97	1	0
Leucocythaemia [description not available]	3.29	2	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	8.29	2	0
Anasarca [description not available]	1.97	1	0
Periphlebitis Periphlebitis is inflammation of the outer coat of a vein or of tissues surrounding the vein.	1.97	1	0
Itching [description not available]	1.97	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	1.97	1	0
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	1.97	1	0
Phlebitis Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).	1.97	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	1.97	1	0
Cancer of Head [description not available]	1.97	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1.97	1	0
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	1.96	1	0
Cancer of Prostate [description not available]	1.96	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1.96	1	0
Lymph Node Metastasis [description not available]	1.97	1	0
Tachyarrhythmia [description not available]	1.96	1	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	1.96	1	0

esorubicin

Description

Cross-References

Synonyms (1)

Research Excerpts

Pharmacokinetics

Dosage Studied

Research

Studies (100)

Study Types

Clinical Trials (3)

Trial Overview

esorubicin

Description

Cross-References

Synonyms (1)

Research Excerpts

Pharmacokinetics

Dosage Studied

Research

Studies (100)

Study Types

Clinical Trials (3)

Trial Overview

Related Drugs (39)

Related Conditions (99)